| Bioactivity | EGFR/AURKB-IN-1 (compound 7) is a dual-targeted EGFR/AURKB inhibitor, and inhibits the phpsphorylations of L858R EGFR and AURKB with IC50s of 0.07 and 1.1, respectively. EGFR/AURKB-IN-1 occupies the hydrophobic region I or the αC-helix out pocket of EGFR and the back pocket of AURKB, inhibiting the growth, division and metastasis of tumor cells, thus can be used for cancer research[1]. |
| Name | EGFR/AURKB-IN-1 |
| CAS | 3008543-34-5 |
| Formula | C23H20N6O |
| Molar Mass | 396.44 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kurup S, et al. Design, synthesis, and evaluation of dual EGFR/AURKB inhibitors as anticancer agents for non-small cell lung cancer. Bioorg Med Chem Lett. 2024 Jan 8:129612. |
EGFR/AURKB-IN-1
CAS: 3008543-34-5 F: C23H20N6O W: 396.44
EGFR/AURKB-IN-1 (compound 7) is a dual-targeted EGFR/AURKB inhibitor, and inhibits the phpsphorylations of L858R EGFR an
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.